Literature DB >> 9351345

Nitric oxide synthases and cardiac muscle. Autocrine and paracrine influences.

J L Balligand1, P J Cannon.   

Abstract

The different cell types comprising cardiac muscle express one or more of the three isoforms (neuronal NOS, or nNOS; inducible NOS, or iNOS; and endothelial NOS, or eNOS) of nitric oxide synthase (NOS). nNOS is expressed in orthosympathetic nerve terminals and regulates the release of catecholamines in the heart. eNOS constitutively expressed in endothelial cells inhibits contractile tone and the proliferation of underlying vascular smooth muscle cells, inhibits platelet aggregation and monocyte adhesion, promotes diastolic relaxation, and decreases O2 consumption in cardiac muscle through paracrinally produced NO. eNOS is also constitutively expressed in cardiac myocytes from rodent and human species, where it autocrinally opposes the inotropic action of catecholamines after muscarinic cholinergic and beta-adrenergic receptor stimulation. iNOS gene transcription and protein expression are induced in all cell types after exposure to a variety of inflammatory cytokines. Aside from participating in the immune defense against intracellular microorganisms and viruses, the large amounts of NO produced autocrinally or paracrinally mediate the vasoplegia and myocardial depression characteristic of systemic immune stimulation and promote cell death through apoptosis. In cardiac myocytes, NO may regulate L-type calcium current and contraction through activation of cGMP-dependent protein kinase and cGMP-modulated phosphodiesterases. Other mechanisms independent of cGMP elevations may operate through interaction of NO with heme proteins, non-heme iron, or free thiol residues on target signaling proteins, enzymes, or ion channels. Given the multiplicity of NOS isoforms expressed in cardiac muscle and of the potential molecular targets for the NO produced, tight molecular regulation of NOS expression and activity at the transcriptional and posttranscriptional level appear to be needed to coordinate the many roles of NO in heart function in health and disease.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9351345     DOI: 10.1161/01.atv.17.10.1846

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  37 in total

Review 1.  Nitric oxide, cell death, and heart failure.

Authors:  Jun-ichi Oyama; Stefan Frantz; Charles Blais; Ralph A Kelly; Todd Bourcier
Journal:  Heart Fail Rev       Date:  2002-10       Impact factor: 4.214

Review 2.  GRK2 as negative modulator of NO bioavailability: Implications for cardiovascular disease.

Authors:  Alessandro Cannavo; Walter J Koch
Journal:  Cell Signal       Date:  2017-01-07       Impact factor: 4.315

Review 3.  Subcellular and cellular locations of nitric oxide synthase isoforms as determinants of health and disease.

Authors:  Cleva Villanueva; Cecilia Giulivi
Journal:  Free Radic Biol Med       Date:  2010-04-11       Impact factor: 7.376

4.  Inhibition of nitric oxide synthesis improves left ventricular contractility in neonatal pigs late after cardiopulmonary bypass.

Authors:  R R Chaturvedi; V E Hjortdal; E V Stenbog; H B Ravn; P White; T D Christensen; A B Thomsen; J Pedersen; K E Sorensen; A N Redington
Journal:  Heart       Date:  1999-12       Impact factor: 5.994

5.  S-nitrosylation in the regulation of gene transcription.

Authors:  Yonggang Sha; Harvey E Marshall
Journal:  Biochim Biophys Acta       Date:  2011-05-24

6.  Vascular Endothelial Growth Factor Increases Endothelial Nitric Oxide Synthase Transcription In Huvec Cells.

Authors:  Esther Koai; Tibisay Rincon Rios; John Edwards
Journal:  Webmedcentral       Date:  2010-11-03

7.  Nitric oxide and promotion of cardiac myocyte apoptosis.

Authors:  Péter Andréka; Thanh Tran; Keith A Webster; Nanette H Bishopric
Journal:  Mol Cell Biochem       Date:  2004-08       Impact factor: 3.396

Review 8.  Nitric oxide homeostasis as a target for drug additives to cardioplegia.

Authors:  B K Podesser; S Hallström
Journal:  Br J Pharmacol       Date:  2007-05-08       Impact factor: 8.739

9.  The role of iNOS-derived NO in the antihypertrophic actions of B-type natriuretic peptide in neonatal rat cardiomyocytes.

Authors:  Tiannan Wang; Ming Yan; Jieyue Li; Xiaoxiang Zheng
Journal:  Mol Cell Biochem       Date:  2007-05-09       Impact factor: 3.396

10.  Hypoxia-induced regulation of nitric oxide synthase in cardiac endothelial cells and myocytes and the role of the PI3-K/PKB pathway.

Authors:  Hans Strijdom; Sven O Friedrich; Suzél Hattingh; Nontuthuko Chamane; Amanda Lochner
Journal:  Mol Cell Biochem       Date:  2008-09-14       Impact factor: 3.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.